How next generation immunotoxin approaches can overcome capillary leak syndrome and be effective anti-cancer agents
AstraZeneca's AZD9291 was approved by the FDA in EGFR T90M mutation positive lung cancer today and is now known as osimertinib or Tagrisso.
Preview of the key topics coming up at the AACR-NCI-EORTC Molecular Targets meeting in Boston, including Pasi Janne's interesting data on T790M negative NSCLC...
Ovarian cancer has lagged behind other solid tumours in terms of development, but this situation may soon change with promising new agents being developed
Clovis present their Phase 2 data with the new rociletinib formulation at EORTC-AACR-NCI in Barcelona
Agios AG-120 IDH1 Inhibitor shows promise in acute myeloid leukemia (AML) according to data to be presented at the EORTC-AACR-NCI Molecular Targets and Cancer Therapeutics Symposium in Barcelona
Clovis have observed responses in T790M positive AND negative lung cancer with rociletinib - implications for the commercial opportunity are discussed in this post.
University College London (UCL) is leading the way in European clinical trials of CAR T Cell therapies that target CD19.